Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.16
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.16
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.12 - C$0.40
Previous CloseN/A
Volume145.39K
Average Volume (3M)89.38K
Market Cap
C$10.40M
Enterprise ValueC$13.07M
Total Cash (Recent Filing)C$434.80K
Total Debt (Recent Filing)C$1.40M
Price to Earnings (P/E)―
Beta-0.01
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Burn TrendTrailing‑Twelve‑Months improvement in cash burn indicates the company has reduced operating cash outflows versus the prior year. That durable trend can extend runway, support continued R&D activity and reduce near‑term financing urgency, improving survival odds absent immediate revenue.
Reduced Debt Versus 2025Lower reported debt relative to 2025 suggests some deleveraging, which improves financial flexibility and reduces future interest/refinancing pressure. This structural improvement can materially ease funding needs and supports ability to negotiate partnerships or bridge financings.
Lean Operating StructureA very small headcount implies a low fixed‑cost base and operational nimbleness, helping preserve cash and extend runway for product development. Over months this structural lean footprint supports disciplined spend management in an early‑stage biotech context.
Bears Say
No Revenue BaseThe absence of revenue means the company lacks internally generated funding to underwrite R&D or commercialization. Structurally, this forces reliance on external capital or partners, increases dilution risk, and lengthens the path to sustainable operations absent clear near‑term commercialization.
Persistent Operating LossesOngoing operating losses and sizable net deficits erode equity and constrain reinvestment capacity. Over a multi‑month horizon these persistent losses heighten recapitalization needs, reduce bargaining power with partners, and limit ability to scale without dilutive financing.
Negative Shareholders' Equity And Stressed Balance SheetNegative shareholders' equity and a small asset base signal accumulated losses and a thin capital cushion. Structurally this raises risk of forced recapitalization, weakens creditor/partner confidence, and limits strategic options when funding needs arise over the coming months.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.12 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$10.40M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Nov 26, 2026 which is in 107 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Jun 18, 2026. The company reported C$0.007 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.007.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of C$0.007 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.